Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $14.8 million.

  • Champions Oncology's Operating Expenses rose 1640.67% to $14.8 million in Q4 2025 from the same period last year, while for Oct 2025 it was $56.3 million, marking a year-over-year increase of 352.48%. This contributed to the annual value of $52.4 million for FY2025, which is 890.26% down from last year.
  • Latest data reveals that Champions Oncology reported Operating Expenses of $14.8 million as of Q4 2025, which was up 1640.67% from $14.5 million recorded in Q3 2025.
  • Champions Oncology's 5-year Operating Expenses high stood at $15.6 million for Q2 2023, and its period low was $9.8 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $13.4 million, with a median of $13.8 million in 2022.
  • Per our database at Business Quant, Champions Oncology's Operating Expenses skyrocketed by 2576.81% in 2022 and then plummeted by 1575.46% in 2024.
  • Champions Oncology's Operating Expenses (Quarter) stood at $11.5 million in 2021, then increased by 23.87% to $14.3 million in 2022, then decreased by 5.23% to $13.5 million in 2023, then fell by 5.7% to $12.8 million in 2024, then increased by 16.41% to $14.8 million in 2025.
  • Its Operating Expenses stands at $14.8 million for Q4 2025, versus $14.5 million for Q3 2025 and $14.4 million for Q2 2025.